Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: A double-blind, randomized controlled trial - 29/08/11
Abstract |
Background: Injection with botulinum A exotoxin reconstituted with preserved saline has been shown to be less uncomfortable than injection with the same toxin reconstituted with preservative-free saline. Objective: We sought to determine whether injection with botulinum toxin type B is similarly less painful when preservative-containing saline is used to further dilute the product. Methods: We conducted a double-blind, randomized controlled trial. A total of 15 consecutive adult patients presenting for treatment of upper face dynamic lines received treatment to one side (left or right) of the face with toxin type B further diluted with preservative-containing saline, and to the other side with toxin type B further diluted with preservative-free saline. Results: Of 15 patients, 13 (87%) reported less pain in the halves of their faces treated with the preservative-containing saline (P = .0006). Pain on the preservative-containing side was on average 32% less among patients as a whole, and 39% less among patients noting some reduction. The 95% confidence interval for pain reduction associated with preservative-containing injection was −46.9% to −16.1%. Neither investigators nor patients observed any difference in clinical efficacy between the 2 treatment sides. Conclusions: Use of preservative-containing saline to further dilute botulinum toxin type B can significantly decrease patient discomfort on injection. (J Am Acad Dermatol 2003;48:875-7.)
Le texte complet de cet article est disponible en PDF.Plan
Supported in part by a grant from Elan Pharmaceuticals. |
|
Conflict of interest: None identified. |
|
Reprint requests: Jeffrey S. Dover, MD, FRCPC, SkinCare Physicians of Chestnut Hill, 1244 Boylston St, Suite 302, Chestnut Hill, MA 02467. E-mail: jdover@skincarephysicians.net. |
|
0190-9622/2003/$30.00 + 0 |
Vol 48 - N° 6
P. 875-877 - juin 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?